The US Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis. CMS also suggested expanding TAVR coverage to patients with asymptomatic severe aortic stenosis and updating procedural and hospital standards. This move is seen as positive for Edwards Lifesciences, which currently holds the only FDA-approved TAVR device for asymptomatic patients, potentially giving the company a competitive edge and accelerating treatment adoption. Edwards Lifesciences shares rose 3.74% following the announcement.
Centene, a major U.S. health insurer, has launched a voluntary separation program allowing eligible employees to apply for buyouts as it faces a significant decline in membership, especially in its Affordable Care Act (ACA) marketplace plans. Members...
Databricks has acquired cybersecurity startup Panther Labs to strengthen its position against competitors like CrowdStrike and Splunk. Panther Labs specializes in consolidating security data streams to enable automated threat responses, addressing th...
SpaceX (SPCX) options began trading, triggering speculation of a gamma squeeze that could drive the stock price to $400. Experts highlight the stock's low tradable float and high call option demand, which may force dealers to buy shares aggressively,...
Laser Photonics has delivered its first robotic laser cleaning system to Vander-Bend Manufacturing, valued at about $800,000. The system automates zinc coating removal from sheet metal panels used in data centers, replacing labor-intensive manual wor...
Velo3D shares jumped over 9% following confirmation by CEO Arun Jeldi that SpaceX's latest Raptor engine is built entirely using Velo3D technology. The company has supplied machines for SpaceX since 2018 and is currently producing parts for the next-...
